Screening for Type 1 and Type 2 Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Ekoé, Jean Marie ^a   Punthakee, Zubin ^a   Ransom, Thomas ^a   Prebtani, Ally P H ^a   Goldenberg, Ronald ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIRETROVIRUS AGENT; GLUCOCORTICOID; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISLET ANTIGEN 2 ANTIBODY; NEUROLEPTIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ACANTHOSIS NIGRICANS; AGE; ARTICLE; BIPOLAR DISORDER; CAUCASIAN; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DEPRESSION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FIRST DEGREE RELATIVE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MACROSOMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PERIPHERAL VASCULAR DISEASE; PREGNANCY DIABETES MELLITUS; PREVALENCE; SCHIZOPHRENIA; SLEEP DISORDERED BREATHING; TRIACYLGLYCEROL BLOOD LEVEL; CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; MASS SCREENING; PRACTICE GUIDELINE; RISK FACTOR;

CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MASS SCREENING; RISK FACTORS;

EID: 84876045068     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.012     Document Type: Article

References (29)

1. Gilmer T.P., O'Connor P.J. The growing importance of diabetes screening. Diabetes Care 2010, 33:1695-1697.
2. Harjutsalo V., Reunanen A., Tuomilehto J. Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring. Diabetes 2006, 55:1517-1524.
3. Decochez K., Truyen I., van der Auwera B., et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 2005, 48:687-694. Belgian Diabetes Registry.
4. Bingley P.J. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study. Diabetes 1996, 45:1720-1728.
5. Knip M., Korhonen S., Kulmala P., et al. Prediction of type 1 diabetes in the general population. Diabetes Care 2010, 33:1206-1212.
6. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006, 29:1263-1268.
7. Rolka D.B., Narayan K.M., Thompson T.J., et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001, 24:1899-1903.
8. Rathmann W., Haastert B., Icks A., et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003, 46:182-189.
9. Van den Donk M., Sandbaek A., Borch-Johnsen, et al. Screening for type 2 diabetes: lessons from the ADDITION-Europe study. Diabet Med 2011, 28:1416-1426.
10. Griffin S.J., Borch-Johnsen K., Davies M.J., et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011, 378:156-167.
11. Simmons R.K., Echouffo-Tcheugui J.B., Sharp S.J., et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012, 380:1741-1748.
12. Raikou M., McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003, 21:543-564.
13. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. JAMA 1998, 280:1757-1763.
14. Kahn R., Alperin P., Eddy D., et al. Age at initiation of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010, 375:1365-1374.
15. Simmons R.K., Rahman M., Jakes R.W., et al. Effect of population screening for type 2 diabetes on mortality: long term follow-up of the Ely cohort. Diabetologia 2011, 54:312-319.
16. Gilles C.L., Lambert P.C., Abrahms K.R., et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost-effectiveness analysis. BMJ 2008, 336:1180-1184.
17. Hoerger T.J., Hicks K.A., Sorensen S.W., et al. Cost-effectiveness of screening for prediabetes among overweight and obese U.S adults. Diabetes Care 2007, 30:2874-2879.
18. Knowler W.C. Screening for NIDDM. Opportunities for detection, treatment, and prevention. Diabetes Care 1994, 17:445-450.
19. Simmons R.K., Echouffo-Tcheugui J.B., Griffin S.J. Screening for type 2 diabetes: an update of evidence. Diabetes Obes Metab 2010, 12:838-844.
20. Leiter L.A., Barr A., Bélanger A., et al. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care 2001, 24:1038-1043. Diabetes Screening in Canada (DIASCAN) Study.
21. Hu G., Qiao Q., Tuomilehto J., et al. Prevalence of the metabolic syndrome and its relation to all- cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004, 164:1066-1076. DECODE Study Group.
22. Glumer C., Vistisen D., Borch-Johnsen K., et al. Risk scores for type 2 diabetes can be applied in some populations but not all. Diabetes Care 2006, 29:410-414. Detect 2 Collaboration.
23. Schmid R., Vollenweider P., Waeber G., et al. Estimating the risk of developing type 2 diabetes: a comparison of several risk scores. The Cohorte Lausannoise Study. Diabetes Care 2011, 34:1863-1868.
24. Robinson C.A., Agarwal G. Validating the CANRISK prognostic model for assessing diabetes risk in Canada's multi-ethnic population. Chron Dis Inj Can 2011, 32:19-31.
25. McKee H.A., D'Arcy P.F., Wilson P.J. Diabetes and schizophrenia: a preliminary study. J Clin Hosp Pharm 1986, 11:297-299.
26. Mukherjee S., Decina P., Bocola V., et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996, 37:68-73.
27. Dixon L., Weiden P., Delahanty J., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000, 26:903-912.
28. Samaras K., Chisholm D.J. Diabetes, insulin resistance and glucose metabolism in HIV infection and its treatment. The Epidemiology of Diabetes Mellitus 2008, 665-675. Wiley Blackwell, Chichester, UK. J.M. Ekoe, M. Rewers, R. Williams (Eds.).
29. Botros N., Concato J., Mohsenin V., et al. Obstructive sleep apnea as a risk factor for type 2 diabetes. Am J Med 2009, 122:1122-1127.